NCT04711382

The Use of Faster Acting Aspart in Type 1 Diabetes Patients

The Use of Faster Acting Aspart in Type 1 Diabetes Patients: Multi-centre Real-world Experience

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 438 (actual)
• Sponsor: University Hospital, Antwerp · Academic / Other
• Sex: All
• Age: 16 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

Detailed description

The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T\<70 and T\<54 mg/dl) and time above range (T\>180 and T\>250 mg/dl). Retrospective analysis Two-center study

Conditions

• Type 1 Diabetes
• Insulin
• Time in Range

Timeline

• Start date: 2018-01-29
• Primary completion: 2020-12-14
• Completion: 2021-01-01
• First posted: 2021-01-15
• Last updated: 2021-01-15

Locations

1 site across 1 country: Belgium